Your browser doesn't support javascript.
loading
Timing the initiation of multiple myeloma.
Rustad, Even H; Yellapantula, Venkata; Leongamornlert, Daniel; Bolli, Niccolò; Ledergor, Guy; Nadeu, Ferran; Angelopoulos, Nicos; Dawson, Kevin J; Mitchell, Thomas J; Osborne, Robert J; Ziccheddu, Bachisio; Carniti, Cristiana; Montefusco, Vittorio; Corradini, Paolo; Anderson, Kenneth C; Moreau, Philippe; Papaemmanuil, Elli; Alexandrov, Ludmil B; Puente, Xose S; Campo, Elias; Siebert, Reiner; Avet-Loiseau, Herve; Landgren, Ola; Munshi, Nikhil; Campbell, Peter J; Maura, Francesco.
Afiliação
  • Rustad EH; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Yellapantula V; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Leongamornlert D; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
  • Bolli N; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Ledergor G; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Nadeu F; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, USA.
  • Angelopoulos N; Patologia Molecular de Neoplàsies Limfoides, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain.
  • Dawson KJ; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029, Madrid, Spain.
  • Mitchell TJ; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
  • Osborne RJ; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
  • Ziccheddu B; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
  • Carniti C; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
  • Montefusco V; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Corradini P; Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin, Italy.
  • Anderson KC; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Moreau P; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Papaemmanuil E; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Alexandrov LB; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Puente XS; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Campo E; CRCINA, SIRIC ILIAD, University Hospital of Nantes, Nantes, France.
  • Siebert R; Computational Oncology Service, Department of Epidemiology & Biostatistics, Center for Computational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
  • Avet-Loiseau H; Department of Cellular and Molecular Medicine and Department of Bioengineering and Moores Cancer Center, University of California, La Jolla, San Diego, CA, USA.
  • Landgren O; Unitat Hematopatologia, Hospital Clínic of Barcelona, Universitat de Barcelona, 08036, Barcelona, Spain.
  • Munshi N; Departamento de Bioquimica y Biologia Molecular, Instituto Universitario de Oncologia (IUOPA), Universidad de Oviedo, Oviedo, Spain.
  • Campbell PJ; Patologia Molecular de Neoplàsies Limfoides, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain.
  • Maura F; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029, Madrid, Spain.
Nat Commun ; 11(1): 1917, 2020 04 21.
Article em En | MEDLINE | ID: mdl-32317634
ABSTRACT
The evolution and progression of multiple myeloma and its precursors over time is poorly understood. Here, we investigate the landscape and timing of mutational processes shaping multiple myeloma evolution in a large cohort of 89 whole genomes and 973 exomes. We identify eight processes, including a mutational signature caused by exposure to melphalan. Reconstructing the chronological activity of each mutational signature, we estimate that the initial transformation of a germinal center B-cell usually occurred during the first 2nd-3rd decades of life. We define four main patterns of activation-induced deaminase (AID) and apolipoprotein B mRNA editing catalytic polypeptide-like (APOBEC) mutagenesis over time, including a subset of patients with evidence of prolonged AID activity during the pre-malignant phase, indicating antigen-responsiveness and germinal center reentry. Our findings provide a framework to study the etiology of multiple myeloma and explore strategies for prevention and early detection.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Regulação Neoplásica da Expressão Gênica / Mieloma Múltiplo Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Regulação Neoplásica da Expressão Gênica / Mieloma Múltiplo Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos